View Item 

Show simple item record

Association of Renal and Cardiovascular Safety With DPP- 4 Inhibitors vs. Sulfonylureas in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease
dc.contributor.authorYang, Chun‐ting
dc.contributor.authorLin, Wei‐hung
dc.contributor.authorLi, Lun‐jie
dc.contributor.authorOu, Huang‐tz
dc.contributor.authorKuo, Shihchen
dc.date.accessioned2021-08-03T18:16:59Z
dc.date.available2022-09-03 14:16:57en
dc.date.available2021-08-03T18:16:59Z
dc.date.issued2021-08
dc.identifier.citationYang, Chun‐ting ; Lin, Wei‐hung ; Li, Lun‐jie ; Ou, Huang‐tz ; Kuo, Shihchen (2021). "Association of Renal and Cardiovascular Safety With DPP- 4 Inhibitors vs. Sulfonylureas in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease." Clinical Pharmacology & Therapeutics (2): 464-472.
dc.identifier.issn0009-9236
dc.identifier.issn1532-6535
dc.identifier.urihttps://hdl.handle.net/2027.42/168511
dc.publisherWiley Periodicals, Inc.
dc.titleAssociation of Renal and Cardiovascular Safety With DPP- 4 Inhibitors vs. Sulfonylureas in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/168511/1/cpt2262-sup-0001-FigS1.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/168511/2/cpt2262_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/168511/3/cpt2262-sup-0002-FigS2.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/168511/4/cpt2262.pdf
dc.identifier.doi10.1002/cpt.2262
dc.identifier.sourceClinical Pharmacology & Therapeutics
dc.identifier.citedreferenceYang, D. & Dalton, J.E. A unified approach to measuring the effect size between two groups using SAS. SAS Global Forum 2012: Statistics and Data Analysis, Paper 335- 2012.
dc.identifier.citedreferenceFilion, K.B. et al. A multicenter observational study of incretin- based drugs and heart failure. N. Engl. J. Med. 374, 1145 - 1154 ( 2016 ).
dc.identifier.citedreferenceKim, K.J. et al. Dipeptidyl peptidase- 4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity- matched cohort study. Cardiovasc. Diabetol. 18, 28 ( 2019 ).
dc.identifier.citedreferenceHsieh, C.- Y. et al. Taiwan- s National Health Insurance Research Database: past and future. Clin. Epidemiol. 11, 349 - 358 ( 2019 ).
dc.identifier.citedreferenceHsieh, H.- M. et al. Economic evaluation of a pre- ESRD pay- for- performance programme in advanced chronic kidney disease patients. Nephrol. Dial. Transplant. 32, 1184 - 1194 ( 2017 ).
dc.identifier.citedreferenceHung, S.- C. et al. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. Lancet Diabetes Endocrinol. 3, 605 - 614 ( 2015 ).
dc.identifier.citedreferenceYang, C.- T., Yang, C.- Y., Ou, H.- T. & Kuo, S. Comparative cardiovascular safety of GLP- 1 receptor agonists versus other glucose- lowering agents in real- world patients with type 2 diabetes: a nationwide population- based cohort study. Cardiovasc. Diabetol. 19, 83 ( 2020 ).
dc.identifier.citedreferenceAustin, P.C. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun. Stat. Simul. Comput. 38, 1228 - 1234 ( 2009 ).
dc.identifier.citedreferenceFine, J.P. & Gray, R.J. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94, 496 - 509 ( 1999 ).
dc.identifier.citedreferenceAustin, P.C., Lee, D.S. & Fine, J.P. Introduction to the analysis of survival data in the presence of competing risks. Circulation 133, 601 - 609 ( 2016 ).
dc.identifier.citedreferenceMosenzon, O. et al. Effect of saxagliptin on renal outcomes in the SAVOR- TIMI 53 trial. Diabetes Care 40, 69 - 76 ( 2017 ).
dc.identifier.citedreferenceXie, Y. et al. Comparative effectiveness of SGLT2 Inhibitors, GLP- 1 receptor agonists, DPP- 4 inhibitors, and sulfonylureas on risk of kidney outcomes: Emulation of a target trial using health care databases. Diabetes Care 43, 2859 - 2869 ( 2020 ).
dc.identifier.citedreferenceHuang, T.- L., Hsiao, F.- Y., Chiang, C.- K., Shen, L.- J. & Huang, C.- F. Risk of cardiovascular events associated with dipeptidyl peptidase- 4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study. PLoS One 14, e0215248 ( 2019 ).
dc.identifier.citedreferenceHung, Y.- C., Lin, C.- C., Huang, W.- L., Chang, M.- P. & Chen, C.- C. Sitagliptin and risk of heart failure hospitalization in patients with type 2 diabetes on dialysis: A population- based cohort study. Sci. Rep. 6, 30499 ( 2016 ).
dc.identifier.citedreferenceChan, S.- Y., Ou, S.- M., Chen, Y.- T. & Shih, C.- J. Effects of DPP- 4 inhibitors on cardiovascular outcomes in patients with type 2 diabetes and end- stage renal disease. Int. J. Cardiol. 218, 170 - 175 ( 2016 ).
dc.identifier.citedreferenceChen, D.- Y. et al. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study. Int. J. Cardiol. 181, 200 - 206 ( 2015 ).
dc.identifier.citedreferenceLiang, C.- Y. et al. Cardiovascular risk of sitagliptin in ischemic stroke patients with type 2 diabetes and chronic kidney disease: A nationwide cohort study. Medicine (Baltimore). 97, e13844 ( 2018 ).
dc.identifier.citedreferenceMcMurray, J.J.V. et al. Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: A randomized placebo- controlled trial. JACC Heart Fail. 6, 8 - 17 ( 2018 ).
dc.identifier.citedreferenceMoen, M.F. et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 4, 1121 - 1127 ( 2009 ).
dc.identifier.citedreferenceBailey, R.A., Wang, Y., Zhu, V. & Rupnow, M.F.T. Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging. BMC Res. Notes 7, 415 ( 2014 ).
dc.identifier.citedreferenceAfkarian, M. et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988- 2014. JAMA 316, 602 - 610 ( 2016 ).
dc.identifier.citedreferenceJitraknatee, J., Ruengorn, C. & Nochaiwong, S. Prevalence and risk factors of chronic kidney disease among type 2 diabetes patients: a cross- sectional study in primary care practice. Sci. Rep. 10, 6205 ( 2020 ).
dc.identifier.citedreferenceRodriguez- Poncelas, A. et al. Prevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 study. BMC Nephrol. 14, 46 ( 2013 ).
dc.identifier.citedreferenceAmerican Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes- 2020. Diabetes Care 43, S98 - S110 ( 2020 ).
dc.identifier.citedreferenceGarber, A.J. et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr. Pract. 26, 107 - 139 ( 2020 ).
dc.identifier.citedreferenceShiba, N. & Shimokawa, H. Chronic kidney disease and heart failure- bidirectional close link and common therapeutic goal. J. Cardiol. 57, 8 - 17 ( 2011 ).
dc.identifier.citedreferenceLo, C. et al. Insulin and glucose- lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database Syst. Rev. 9, CD011798 ( 2018 ).
dc.identifier.citedreferencevan Dalem, J. et al. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. BMJ 354, i3625 ( 2016 ).
dc.identifier.citedreferenceScirica, B.M. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369, 1317 - 1326 ( 2013 ).
dc.identifier.citedreferenceWhite, W.B. et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 369, 1327 - 1335 ( 2013 ).
dc.identifier.citedreferenceZannad, F. et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double- blind trial. Lancet 385, 2067 - 2076 ( 2015 ).
dc.identifier.citedreferenceGreen, J.B. et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 373, 232 - 242 ( 2015 ).
dc.identifier.citedreferenceCornel, J.H. et al. Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: Outcomes from TECOS. Diabetes Care 39, 2304 - 2310 ( 2016 ).
dc.identifier.citedreferenceRosenstock, J. et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial. JAMA 321, 69 - 79 ( 2019 ).
dc.identifier.citedreferenceRosenstock, J. et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: The CAROLINA randomized clinical trial. JAMA 322, 1155 - 1166 ( 2019 ).
dc.identifier.citedreferencePerkovic, V. et al. Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: Secondary analysis of the CARMELINA randomized trial. Diabetes Care 43, 1803 - 1812 ( 2020 ).
dc.identifier.citedreferenceOu, S.- M. et al. Effects on clinical outcomes of adding dipeptidyl peptidase- 4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus. Ann. Intern. Med. 163, 663 - 672 ( 2015 ).
dc.identifier.citedreferenceOu, H.- T., Chang, K.- C., Li, C.- Y. & Wu, J.- S. Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third- line antidiabetic drugs in patients with type 2 diabetes. Br. J. Clin. Pharmacol. 83, 1556 - 1570 ( 2017 ).
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cpt2262-sup-0001-FigS1.pdf
Size:
88.21KB
Format:
PDF
View/Open
Name:
cpt2262_am.pdf
Size:
337.3KB
Format:
PDF
View/Open
Name:
cpt2262-sup-0002-FigS2.pdf
Size:
28.69KB
Format:
PDF
View/Open
Name:
cpt2262.pdf
Size:
221.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.